mRNA Encoded Masked IL-12 Molecule / CytomX, Moderna - LARVOL DELTA

An mRNA-encoded masked IL-12 improves systemic tolerability while maintaining anti-tumor efficacy in preclinical studies (AACR 2025) - "Using CytomX proprietary PROBODY® Therapeutics masking technology and Moderna mRNA technology, we describe a novel product concept of an mRNA encoded masked IL-12 molecule that is designed to have reduced activity systemically...Most importantly, masked IL-12 mRNA dosed systemically resulted in complete remission of tumors in all dose levels and demonstrated protease-dependent intra-tumoral activation and efficacy. Taken together, these data show a novel and attractive engineering approach to develop an mRNA-encoded IL-12 therapeutic that significantly improves tolerability while maintaining potent anti-tumor activity."

Preclinical • Oncology • IFNG • IL12A

CytomX Therapeutics Presents Preclinical Data for mRNA Encoded Masked IL-12 Molecule in Collaboration with Moderna at AACR Annual Meeting (GlobeNewswire) - "CytomX Therapeutics...announced new preclinical data in collaboration with Moderna on an mRNA encoded masked IL-12 molecule....'By combining CytomX’s proprietary PROBODY masking technology and Moderna’s mRNA technology, we have created an mRNA therapeutic encoding a masked IL-12, designed to be selectively activated within the tumor microenvironment (TME), with limited systemic activity'."

Preclinical • Oncology